Cancer Research · 2017 · 220 citations · 18 references
Life SciencesImmunologyOncologyCancer ImmunologyImmunotherapyTumor ImmunologyAntitumor T Cell ResponsesCancer ImmunotherapyChimeric Antigen Receptor T-cell TherapyImmune Checkpoint RegulationImmunotherapy For Solid TumorsT Cell Responses To TumorsAdenovirus BiologyAdenovirus VectorsHumanized Xenograft ModelsPd-l1 BlockadeProinflammatory MediatorsSolid Tumor Car T-cell TherapyT Cell Checkpoint InhibitionT Cell-mediated Tumor Killing
Abstract Chimeric antigen receptor–modified T cells (CAR T cells) produce proinflammatory cytokines that increase expression of T-cell checkpoint signals such as PD-L1, which may inhibit their functionality against solid tumors. In this study, we evaluated in human tumor xenograft models the proinflammatory properties of an oncolytic adenovirus (Onc.Ad) with a helper-dependent Ad (HDAd) that expresses a PD-L1 blocking mini-antibody (mini-body; HDPDL1) as a strategy to enhance CAR T-cell killing. Coadministration of these agents (CAd-VECPDL1) exhibited oncolytic effects with production of PD-L1 mini-body locally at the tumor site. On their own, HDPDL1 exhibited no antitumor effect and CAd-VECPDL1 alone reduced tumors only to volumes comparable to Onc.Ad treatment. However, combining CAd-VECPDL1 with HER2.CAR T cells enhanced antitumor activity compared with treatment with either HER2.CAR T cells alone or HER2.CAR T cells plus Onc.Ad. The benefits of locally produced PD-L1 mini-body by CAd-VECPDL1 could not be replicated by infusion of anti-PD-L1 IgG plus HER2.CAR T cells and coadministration of Onc.Ad in an HER2+ prostate cancer xenograft model. Overall, our data document the superiority of local production of PD-L1 mini-body by CAd-VECPDL1 combined with administration of tumor-directed CAR T cells to control the growth of solid tumors. Cancer Res; 77(8); 2040–51. ©2017 AACR.
18
A mutant oncolytic adenovirus targeting the Rb pathway produces anti-glioma effect in vivo
Juàn Fueyo, Candelaria Gomez‐Manzano, Ramón Alemany et al. · Oncogene · 2000 · 772 citations
David F. McDermott, Jeffrey A. Sosman, Mario Sznol et al. · Journal of Clinical Oncology · 2016 · 558 citations
Medicine, Oncology, Pharmacology +17